



SUVEN LIFE SCIENCES LTD

Off:SDE Serene Chambers,6th floor, Road No.5, Banjara Hills, Hyderabad - 500 034
STATEMENT OF UN AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE
QUARTER ENDED JUNE 30, 2020.

		Rs. In Lakhs			
PART - I		STANDALONE			
Sl. No.	PARTICULARS	For the Quarter Ended			For the year ended
		30/06/2020	31/03/2020	30/06/2019	31/03/2020
		UN AUDITED	Refer No 8	UN AUDITED	Audited
		(1)	(2)	(3)	(4)
1	Income				
	Revenue from operations	142.86	866.00	159.49	1,441.47
	Other Income	252.93	299.71	280.29	1,403.63
	Total income	395.79	1,165.71	439.78	2,845.10
2	Expenses				
	a) Cost of materials consumed	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-
	c) Employee benefits expense	340.67	348.16	448.96	1,459.51
	d) Finance costs	21.93	23.21	10.61	54.03
	e) Depreciation and amortisation expense	106.49	105.24	84.52	416.87
	f) Manufacturing Expenses	-	-	-	-
	g) R & D Expenses	494.73	576.33	628.38	2,594.44
	h) Other Expenses	86.43	149.25	214.15	913.86
	Total expenses	1,050.25	1,202.19	1,386.62	5,438.71
3	Profit before exceptional items & Tax (1-2)	(654.46)	(36.48)	(946.84)	(2,593.61)
4	Exceptional Items	-	-	-	-
5	Profit before Tax (3-4)	(654.46)	(36.48)	(946.84)	(2,593.61)
6	Tax Expenses				
	a) Current tax	-	197.18	-	197.18
	b) Deferred tax	(246.72)	22.69	(1,401.27)	(1,415.47)
7	Net Profit/ (Loss) for the period/year(5-6)	(407.74)	(256.35)	454.43	(1,375.32)
8	Other Comprehensive Income				
8.a	(i) Items that will not be reclassified to profit or loss	(11.35)	(28.88)	(1.06)	(45.41)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	3.97	10.09	0.37	15.87
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total other Comprehensive Income	(7.38)	(18.79)	(0.69)	(29.54)
9	Total Comprehensive Income for the period (7+8)	(415.12)	(275.14)	453.74	(1,404.86)
10	Paid-up equity share capital	1,272.82	1,272.82	1,272.82	1,272.82
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity				37,494.53
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :				
	a) Basic	(0.32)	(0.20)	0.36	(1.08)
	b) Diluted	(0.32)	(0.20)	0.36	(1.08)
		(not annualised)	(not annualised)	(not annualised)	

PART - I		CONSOLIDATED			
Sl. No.	PARTICULARS	For the Quarter Ended			For the year ended
		30/06/2020	31/03/2020	30/06/2019	31/03/2020
		UN AUDITED	Refer No 8	UN AUDITED	Audited
		(1)	(2)	(3)	(4)
1	Income				
	Revenue from operations	142.86	866.00	159.49	1,441.47
	Other Income	252.93	299.71	280.29	1,403.63
	Total income	395.79	1,165.71	439.78	2,845.10
2	Expenses				
	a) Cost of materials consumed	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress	-	-	-	-
	c) Employee benefits expense	413.82	433.21	515.99	1,740.91
	d) Finance costs	22.43	23.23	10.90	55.14
	e) Depreciation and amortisation	106.49	105.24	84.52	416.87
	f) Manufacturing Expenses	-	-	-	-
	g) R & D Expenses	1,053.67	2,783.77	3,603.94	10,322.64
	h) Other Expenses	95.03	156.21	229.00	949.62
	Total expenses	1,691.44	3,501.66	4,444.35	13,485.18
3	Profit before exceptional items , Tax (1-2)	(1,295.65)	(2,335.95)	(4,004.57)	(10,640.08)
4	Exceptional Items- (Ref Note:7)	-	-	-	-
5	Profit before Tax (3-4)	(1,295.65)	(2,335.95)	(4,004.57)	(10,640.08)
6	Tax Expenses				
	a) Current tax	-	197.18	-	197.18
	b) Deferred tax	(246.72)	22.69	(1,401.27)	(1,415.47)
7	Net Profit/ (Loss) for the period/year(5-6)	(1,048.93)	(2,555.82)	(2,603.30)	(9,421.79)
8	Other Comprehensive Income				
8.a	(i) Items that will not be reclassified to profit or loss	(11.35)	(28.89)	(1.06)	(45.41)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	3.97	10.10	0.37	15.87
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total other Comprehensive Income	(7.38)	(18.79)	(0.69)	(29.54)
9	Total Comprehensive Income for the period (7+ 8)	(1,056.31)	(2,574.61)	(2,603.99)	(9,451.33)
10	Paid-up equity share capital Face Value of the Share	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00
11	Other Equity	-	-	-	13,062.02
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :				
	a) Basic	(0.82)	(2.01)	(2.05)	(7.40)
	b) Diluted	(0.82)	(2.01)	(2.05)	(7.40)
		(not annualised)	(not annualised)	(not annualised)	

NOTES:-

1) The above unaudited financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 11,2020 . The above results have been subjected to limited review by the statutory auditors of the company

2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.

3) The consolidated financial results include the results of the 100 % subsidiary of Suven Neurosciences , Inc

4).The National Company Law Tribunal, Hyderabad Bench vide its order dated January 06,2020 has approved the scheme of arrangement for demerger of CRAMS undertaking of the Company to Suven Pharmaceuticals Limited (SPL) with effect from October 01, 2018 (the appointed date). The Scheme became effective from October 01, 2018. Pursuant to the Scheme, all the assets, liabilities, income and expenses of the CRAMS undertaking have been transferred to SPL from the appointed date.

The Company (SLSL) has to transfer the statutory and regulatory licenses with in India and Outside India so as to enable SPL to carry on the business in its name. The process of obtaining the approvals from all departments is a lengthy process. In order to maintain the continuity of the business during these statutory approvals period, the Company is continuing the CRAMS business in its own name on behalf of SPL. However, all such operations were recorded in the books of SPL, the same may be continued till the migration of all licenses in the name of SPL.

5) Pursuant to a fire accident on April 26, 2020 at Jeedimetla Plant , certain fixed assets and other contents in buildings was damaged. The company has lodged an initial estimate of loss with insurance company and survey is currently ongoing. During the quater ended June 30, 2020, the company has written off net book value of assets aggregating Rs 72.65 Lakhs and recognised a minimum insurance claim receivable for equivalent amount .

6) The COVID-19 impact on the business and going concern assumption of SLSL and its subsidiary: COVID-19 had not impacted the company's research operations, which includes our subsidiary, Suven Neurosciences, Inc.

7) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.

8) The figures for the quarter ended March 31, 2020 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to third quarter of the financial year ended March 31 , 2020

9) The corresponding previous period figures have been regrouped / reclassified where ever necessary.

For SUVEN LIFE SCIENCES LTD

**Place : Hyderabad
Date : August 11 , 2020**

**VENKAT JASTI
Chairman & CEO
DIN: 00278028**